Search
Close
Search
Advanced Search
Search Menu
AI Discovery Assistant

Introduction and Aims: To assess potential risk factors for the development of venous thromboembolic events in patients with anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitides.

Methods: 417 patients with appropriate follow-up data enrolled in randomised controlled trials conducted by the European Vasculitis Society (EUVAS) were identified. Univariate and multivariate analyses were performed in order to validate previously proposed and identify novel risk factors.

Results: Venous thromboembolism (VTE) occurred in 41 of 417 (9.8%) patients. Multivariate analysis retained Birmingham Vasculitis Activity Score (BVAS, OR 1.05, P=0.013), subsequent malignancy (OR 2.47, P=0.027), cutaneous (OR (4.07, P=0.001), gastrointestinal (OR 5.6, P=0.002) and mucous membrane / eye involvement (OR 2.73, P=0.005) as significant predictors for the development of VTE.

Conclusions: Our results highlight a role of higher disease activity and cutaneous, gastrointestinal and mucous membrane / eye involvement as risk factors to predict thromboembolic events. Moreover, our analysis revealed the association of a classic risk factor (malignancy) with VTE risk in patients with ANCA-associated vasculitides.

Open in new tab

Table 1. In multivariate analysis, potential risk factors.

6 models (each adjusted for age, gender, baseline creatinine)OR(95 % CI)p-value
BVAS1.05(1.01-1.10)0.013
Cutaneous4.07(1.97-8.37)0.001
Diabetes during follow-up0.60(0.20-1.77)0.355
GI5.60(1.93-16.22)0.002
Mucous Membrane / Eyes2.73(1.35-5.50)0.005
Subsequent Cancer2.47(1.11-5.52)0.027
6 models (each adjusted for age, gender, baseline creatinine)OR(95 % CI)p-value
BVAS1.05(1.01-1.10)0.013
Cutaneous4.07(1.97-8.37)0.001
Diabetes during follow-up0.60(0.20-1.77)0.355
GI5.60(1.93-16.22)0.002
Mucous Membrane / Eyes2.73(1.35-5.50)0.005
Subsequent Cancer2.47(1.11-5.52)0.027
Open in new tab

Table 1. In multivariate analysis, potential risk factors.

6 models (each adjusted for age, gender, baseline creatinine)OR(95 % CI)p-value
BVAS1.05(1.01-1.10)0.013
Cutaneous4.07(1.97-8.37)0.001
Diabetes during follow-up0.60(0.20-1.77)0.355
GI5.60(1.93-16.22)0.002
Mucous Membrane / Eyes2.73(1.35-5.50)0.005
Subsequent Cancer2.47(1.11-5.52)0.027
6 models (each adjusted for age, gender, baseline creatinine)OR(95 % CI)p-value
BVAS1.05(1.01-1.10)0.013
Cutaneous4.07(1.97-8.37)0.001
Diabetes during follow-up0.60(0.20-1.77)0.355
GI5.60(1.93-16.22)0.002
Mucous Membrane / Eyes2.73(1.35-5.50)0.005
Subsequent Cancer2.47(1.11-5.52)0.027
© The Author 2016. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
Issue Section:
Oral session > Tuesday, May 24th, 2016: Free Communications (sorted by session) > GLOMERULONEPHRITIS: CLINICAL AND EXPERIMENTAL 2
Download all slides

Comments

0 Comments
Comments (0)
Submit a comment
You have entered an invalid code
Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.